Sibutramine on Cardiovascular Outcome

S ibutramine, a combined norepi-nephrine and serotonin reuptakeinhibitor, is effective in the man-agement of obese patients requiring phar-macotherapy as part of a multimodal approach to weight loss. It improves in-sulin resistance markers, glucose metab-olism, and atherogenic dyslipidemia in both diabetic and nondiabetic patients, most of these effects resulting fromweight loss. However, sibutramine exerts a pe-ripheral sympathomimetic effect that induces a moderate increase in heart rate and attenuates the reduction in blood pressure attributable to weight loss or even slightly increases blood pressure. Since 2002, several cardiovascular adverse events